Company news

Eli Lilly and Company news in 2025

Eli Lilly and Company's news releases, calls and decks from 2025, newest first.

View company

ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly

December 25, 2025

Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies

December 24, 2025

FlyteHealth to Expand Direct Access to Obesity Management Medication for Employers

December 22, 2025

Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial

December 18, 2025

MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics

December 17, 2025

Lilly to participate in J.P. Morgan Healthcare Conference

December 16, 2025

Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer

December 12, 2025

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial

December 11, 2025

Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama

December 9, 2025

Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition

December 9, 2025

Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL

December 9, 2025

Lilly declares first-quarter 2026 dividend

December 8, 2025

Carolyn Bertozzi returns to Lilly board of directors

December 8, 2025

Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)

December 7, 2025

U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor

December 3, 2025

Abemaciclib Research Report 2025: Eli Lilly and Company Dominates the $1.6 Billion Market - Long-term Forecasts to 2029 and 2034

December 2, 2025

Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly

December 1, 2025

BMO Launches New CDRs With Exposure to U.S. Stocks Including Microsoft, Eli Lilly, Exxon, Chevron and Robinhood

November 26, 2025

Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium

November 24, 2025

Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting

November 24, 2025

Ilant Health Enhances Comprehensive Cardiometabolic Care with Direct Contracting for Obesity Management Medicine for Employers

November 21, 2025

Goodpath Expands Access to Obesity Management Care and Medications Through New Transparent Offering

November 21, 2025

9amHealth to Expand Access to Obesity Management Treatment through New Employer Health Benefits Offering

November 21, 2025

VIPC Signs MOU with AstraZeneca, Eli Lilly, Merck to Develop the Virginia Center for Advanced Pharmaceutical Manufacturing to Train Workforce of the Future

November 20, 2025

Exploring the global transformation of health care with Eli Lilly's CEO Dave Ricks

November 19, 2025

Lilly announces plans to open Lilly Gateway Labs site in Philadelphia

November 19, 2025

Breakthrough Properties and Eli Lilly and Company Partner to Bring Lilly Gateway Labs to Newly-Developed 2300 Market Street in Philadelphia

November 19, 2025

Lilly to participate in Citi's 2025 Global Healthcare Conference

November 18, 2025

ObesityWeek 2025: Breakthrough Results Reshaping the Obesity Market Landscape | DelveInsight

November 13, 2025

Insilico and Lilly Enter a Research & Licensing Collaboration to Advance AI-Driven Drug Discovery

November 10, 2025

Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'

November 10, 2025

SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly

November 8, 2025

Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

November 6, 2025

Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans

November 6, 2025

Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight

November 6, 2025

Alliance for Building Better Medicine and the Virginia Innovation Partnership Celebrate $120 Million Investment from AstraZeneca, Eli Lilly, and Merck to Advance Virginia's Advanced Pharmaceutical Manufacturing Workforce

November 5, 2025

Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide

November 3, 2025

Weekly Recap: 12 Tech Press Releases You Need to See

October 31, 2025

Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance

October 30, 2025

Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States

October 29, 2025

Calls in 2025

Decks in 2025